| Tufts University, B.S. | |
| Summa cum laude |
Mr. Bernitz has over 15 years experience in the pharmaceutical and biotechnology industry. He brings extensive experience in business, corporate and product development as well as commercial operations to Concert. Most recently he served as Chief Executive Officer of Histogenics Corporation. Before Histogenics, he held the position Senior Vice President, Business and Commercial Development at Coley Pharmaceutical Group, where he led the negotiation of a $515 million licensing deal with Pfizer, which subsequently acquired Coley. Mr. Bernitz was also a senior executive at Organogenesis, and has held senior positions in business development, alliance management and product development with Dyax Corp. and Merck & Co. Prior to his life sciences experience he worked in private equity and was a consultant at McKinsey & Co, Inc.
